Vaccines MDPI

🏆 Vaccines Travel Award 2026 – Applications Now Open

Since 2018, the Vaccines Travel Award has supported junior scientists in sharing their latest research at international conferences.

Award details:

– CHF 500;
– A certificate.

👥Number of Winners: 2

🔆Eligibility and Requirements
– Postdoctoral fellows or PhD students;
– Plans to attend an international conference in 2027 (oral presentation or poster).

🔆List of Documents for Application
– Information of the conference the applicant is planning to attend and the abstract that will be submitted;
– Curriculum Vitae and list of publications;
– Justification letter describing the focus of the research (max. 800 words);
– Letter of recommendation from the supervisor, research director, or department head, which also confirms the applicant’s status.

🔗 Learn more & apply: https://brnw.ch/21x2umb

Vaccines Vaccines, an international, peer-reviewed Open Access journal.

🎉 We are pleased to announce the launch of a new Special Issue!

"Resurgence of Measles in the United States—Transmission Drivers, Dynamics, and Public Health Implications in Undervaccinated Clusters"
👤 Guest Editor: Dr. M. Lelinneth (Len) B. Novilla

We invite authors to submit research for addressing the following key points:

1. Transmission Modeling and Forecasting
2. Vaccine Coverage and Post-Pandemic Gap
3. Vaccine Misinformation and Trust Issues
4. Outbreak Response and Public Health Infrastructure
5. Vaccine Mandates and Policies
6. Economic and Health System Burden
7. Travel, Genomic Epidemiology and Border Health

📅 Deadline for manuscript submissions: 30 April 2027
👉 For more information and to submit please visit: https://brnw.ch/21x2ucU

Resurgence of Measles in the United States—Transmission Drivers, Dynamics, and Public Health Implications in Undervaccinated Clusters Vaccines, an international, peer-reviewed Open Access journal.

📢 Special Issue update – Vaccines

Vaccine Epidemiology and Population Health

We are delighted to announce that a new Guest Editor, Dr. Charles Shey Wiysonge, has joined this Special Issue, and will co-lead it together with Dr. Jacques Lukenze Tamuzi.

📅 Deadline for manuscript submissions: 31 August 2026

🔗 Learn more and submit your work: https://brnw.ch/21x2tRr

The issue remains open for submissions. We invite original research, reviews, and methodological advances in relevant fields.

Vaccine Epidemiology and Population Health Vaccines, an international, peer-reviewed Open Access journal.

🎉 We are excited to announce the publication of a newly published paper in our special issue "Mucosal Immunity and Vaccine"! 📚

📝 "Mucosal Delivery of Recombinant SARS-CoV-2 Spike Receptor-Binding Domain Antigen Containing Immune-Stimulating Peptides Induces Protective Immune Responses Against Viral Infection in huACE2 Mice," authored by Byeol-Hee Cho, Ju Kim and Yong-Suk Jang.

This study showed that Co4B targets Siglec F on M cells in mucosal tissues, enhancing antigen delivery to the mucosal immune system and inducing antigen-specific immune responses. Recombinant SARS-CoV-2 antigen conjugated with Co4B and HBD2 elicited effective humoral and cellular immune responses in both mucosal and systemic compartments, supporting their potential as a vaccine platform.

👉 We invite you to read the full article here: https://brnw.ch/21x2tvg 🌟

This special issue, led by Prof. Dr. Xingmin Sun and Dr. Yongqun He (Oliver), is still welcoming submissions! ✍️

For more information about the special issue, please visit: https://brnw.ch/21x2tvf 🌐

Mucosal Delivery of Recombinant SARS-CoV-2 Spike Receptor-Binding Domain Antigen Containing Immune-Stimulating Peptides Induces Protective Immune Responses Against Viral Infection in huACE2 Mice Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through the interaction between the spike protein receptor-binding domain (RBD) and the human angiotensin-converting enzyme 2 (hACE2) receptor, which is expressed on epithelial cells in various tissues, inclu...

🎉 We are excited to announce the publication of the first paper in our special issue "Mechanisms of Inflammation in Long-COVID/Post-COVID-Vaccination Syndrome"! 📚

📝 "Autoimmune Features of Post-COVID-19 Vaccination Syndrome and Their Impacts on the Renin–Angiotensin System," authored by Paolo Bellavite, Giuseppe Di Fede, Mauro Mantovani and Elisabetta Zanolin.

👉 We invite you to read the full article here: https://brnw.ch/21x2tuk 🌟

This special issue, led by Dr. Loredana Frasca, is still welcoming submissions! ✍️

For more information about the special issue, please visit: https://brnw.ch/21x2tuj 🌐

Autoimmune Features of Post-COVID-19 Vaccination Syndrome and Their Impacts on the Renin–Angiotensin System One of the most critical aspects of post-acute COVID-19 syndrome (PACS) and post-acute COVID-19 vaccination syndrome (PACVS) is the presence of autoantibodies. These autoantibodies are directed against various receptors in the autonomic and cardiovascular systems, including those targeting proteins ...

🏆 Editor’s Choice

Evaluating the Immunogenicity, Efficacy, and Effectiveness of Recombinant Zoster Vaccine for Global Public Health Policy

by Lucy R. Williams, Joachim Hombach and Melanie Marti

The recombinant zoster vaccine (RZV) is effective in reducing the risk of HZ and its associated complications. Protection is long-lasting and the vaccine is suitable for older and immunocompromised populations. However, the decision to incorporate the vaccine into national policies depends on additional factors (e.g., cost-effectiveness), which may be difficult to characterize without an understanding of the global disease burden.

🔗 Read the full text here: https://brnw.ch/21x2tlT

Evaluating the Immunogenicity, Efficacy, and Effectiveness of Recombinant Zoster Vaccine for Global Public Health Policy Background: Herpes zoster (HZ) is a painful neurocutaneous disease caused by the varicella-zoster virus. The recombinant zoster vaccine (RZV) is becoming increasingly incorporated into national vaccination schedules. We aimed to evaluate RZV from a global public health policy perspective. Methods: W...

🎉 We are excited to announce the publication of the first paper in our special issue "Mechanisms of Inflammation in Long-COVID/Post-COVID-Vaccination Syndrome"! 📚

📝 "Autoimmune Features of Post-COVID-19 Vaccination Syndrome and Their Impacts on the Renin–Angiotensin System," authored by Paolo Bellavite, Giuseppe Di Fede, Mauro Mantovani and Elisabetta Zanolin.

👉 We invite you to read the full article here: https://brnw.ch/21x2tjN 🌟

This special issue, led by Dr. Loredana Frasca, is still welcoming submissions! ✍️

For more information about the special issue, please visit: https://brnw.ch/21x2tjO 🌐

Autoimmune Features of Post-COVID-19 Vaccination Syndrome and Their Impacts on the Renin–Angiotensin System One of the most critical aspects of post-acute COVID-19 syndrome (PACS) and post-acute COVID-19 vaccination syndrome (PACVS) is the presence of autoantibodies. These autoantibodies are directed against various receptors in the autonomic and cardiovascular systems, including those targeting proteins ...

🎉 We are pleased to announce the launch of a new Special Issue!

"mRNA Vaccines in Disease Prevention and Treatment"
👤 Guest Editor: Prof. Dr. Jorge H. Leitão

we welcome papers and comprehensive reviews on topics from the design and optimization of mRNA constructs, delivery systems, and adjuvants to applications to prevent and treat specific infectious diseases caused by viruses, bacteria, and parasites, as well as cancer prevention and treatment. Studies on the optimal routes of administration for maximal immunological protection and epidemiological studies on adverse reactions to mRNA vaccination are also welcome.

📅 Deadline for manuscript submissions: 31 March 2027
👉 For more information and to submit please visit: https://brnw.ch/21x2s7L

mRNA Vaccines in Disease Prevention and Treatment Vaccines, an international, peer-reviewed Open Access journal.

🏆 Editor’s Choice

Pre-Existing Anti-Vector Immunity to Adenovirus-Inspired VLP Vaccines Shows an Adjuvant-Dependent Antagonism

By Salomé Gallet, Dalil Hannani, Sebastian Dergan-Dylon,
Emilie Vassal-Stermann, Isabelle Bally, Christopher Chevillard,
Daphna Fenel, Olivier Epaulard, Pascal Poignard and Pascal Fender.

The data suggest that the immune status against immunizing VLPs must be taken into consideration when designing immunization protocols. Importantly, the effects of prior immunity may vary depending on the nature of the protocol, including factors such as adjuvant use.

🔗 Read the full article: https://brnw.ch/21x2rRo

Pre-Existing Anti-Vector Immunity to Adenovirus-Inspired VLP Vaccines Shows an Adjuvant-Dependent Antagonism Background/Objectives: The use of virus-like particles (VLPs) in vaccinology has expanded significantly in recent years. VLPs have the advantage of being non-infectious while effectively stimulating B cell responses through the repetitive presentation of epitope motifs on their surface. Since VLPs a...

📢 Special Issue Update – Vaccines

We are pleased to share that 5 articles have already been published in the Special Issue "Immunobiology of Mycobacterium tuberculosis and Its Implication in Vaccine Design".

The issue remains open for submissions, we invite you to contribute your research to this growing collection.

👤 Guest Editors: Dr. Tony W. Ng and Prof. Dr. Steven A. Porcelli

We invite authors to submit work that they view as relevant to these goals, including, but not limited to, the following topics:

1. Intravenous BCG and other nontraditional routes of vaccine administration.
2. Newly recognized TB antigens, including subdominant and cryptic antigens or antigenic decoys.
3. Adjuvant formulations.
4. Eradicating dormant and persistent forms of Mtb.
5. Prime-boost vaccination with attenuated Mtb or BCG strains.
6. Mycobacterium-specific T and B cell responses.

📅 Deadline for manuscript submissions: 31 August 2026
🔗 View published articles & submit your work: https://brnw.ch/21x2rsU

Immunobiology of Mycobacterium tuberculosis and Its Implication in Vaccine Design Vaccines, an international, peer-reviewed Open Access journal.

🎉 We are delighted to announce the launch of a new Special Issue in Vaccines:

"Vaccine Advancement, Efficacy and Safety: Feature Papers"

This Special Issue is led by our Section Editor-in-Chief, Dr. Pedro Plans-Rubió.

We welcome contributions concerning vaccine efficacy and effectiveness; vaccine safety; vaccine platforms; the economic and cost-effectiveness studies of vaccines; vaccine trials; interventions to increase vaccination coverage at national, regional, and local levels; factors of vaccine hesitancy and vaccine confidence; and the performance and quality of vaccination programs.

📅 Deadline for manuscript submissions: 28 February 2027
👉 For more information and to submit please visit: https://brnw.ch/21x2rry

Vaccine Advancement, Efficacy and Safety: Feature Papers Vaccines, an international, peer-reviewed Open Access journal.